Abstract:The original etiology of Alzheimer's disease (AD) is the deposition of amyloid-beta (Aβ) proteins, which starts from the aggregation of the Aβ oligomers. The optimal therapeutic strategy targeting Aβ oligomer aggregation is the development of AD vaccines. Despite the fact that positive progress has been made for experimental attempts at AD vaccines, the physicochemical and even structural properties of these AD vaccines remain unclear. In this study, through immunoinformatic and molecular dynamics (MD) simulations, we first designed and simulated an alternative of vaccine TAPAS and found that the structure of the alternative can reproduce the 3D conformation of TAPAS determined experimentally. Meanwhile, immunoinformatic methods were used to analyze the physicochemical properties of TAPAS, including immunogenicity, antigenicity, thermal stability, and solubility, which confirm well the efficacy and safety of the vaccine, and validate the scheme reliability of immunoinformatic and MD simulations in designing and simulating the TAPAS vaccine. Using the same scheme, we predicted the 3D conformation of the optimized ACI-24 peptide vaccine, an Aβ peptide with the first 15 residues of Aβ42 (Aβ1-15). The vaccine was verified once to be effective against both full-length Aβ1-42 and truncated Aβ4-42 aggregates, but an experimental 3D structure was absent. We have also explored the immune mechanism of the vaccine at the molecular level and found that the optimized ACI-24 and its analogues can block the growth of either full-length Aβ1-42 or truncated Aβ4-42 pentamer by contacting the hydrophobic residues within the N-terminus and β1 region on the contact surface of either pentamer. Additionally, residues (D1, D7, S8, H13, and Q15) were identified as the key residues of the vaccine to contact either of the two Aβ oligomers. This work provides a feasible implementation scheme of immunoinformatic and MD simulations for the development of AD small peptide vaccines, validating the power of the scheme as a parallel tool to the experimental approaches and injecting molecular-level information into the understanding and design of anti-AD vaccines.

Short Amyloid-Beta Immunogens Show Strong Immunogenicity and Avoid Stimulating Pro-Inflammatory Pathways in Bone Marrow-Derived Dendritic Cells from C57BL/6J Mice in Vitro

Vaccines targeting the primary amino acid sequence and conformational epitope of amyloid‐β had distinct effects on neuropathology and cognitive deficits in EAE/AD mice

The Combined Treatment of Amyloid-Β1-42-stimulated Bone Marrow–derived Dendritic Cells Plus Splenocytes from Young Mice Prevents the Development of Alzheimer's Disease in APPswe/PSENldE9 Mice

Amyloid-Beta Immunotherapy for the Prevention and Treatment of Alzheimer Disease: Lessons from Mice, Monkeys, and Humans

Effects of a 15-Amino-acid Isoform of Amyloid- Β Expressed by Silkworm Pupae on B6C3-Tg Alzheimer’s Disease Transgenic Mice

A pentavalent peptide vaccine elicits Aβ and tau antibodies with prophylactic activity in an Alzheimer's disease mouse model

New progress in active immunotherapy targeting to amyloid beta

Prophylactic immunotherapy of Alzheimer's disease using recombinant amyloid-β B-cell epitope chimeric protein as subunit vaccine

Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis

Molecular Integrative Study on Inhibitory Effects of Pentapeptides on Polymerization and Cell Toxicity of Amyloid-β Peptide (1–42)

Impact of Alternating Amino Acid Sequences on Beta-Amyloid-induced Neurotoxicity and Neuroinflammation in Alzheimer's Disease.

Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer’s Disease Model Mice

Progress on Immunization with Amyloid-Beta in A Mouse Model of Alzheimer'S Disease

Prediction of the 3D conformation of a small peptide vaccine targeting Aβ42 oligomers

A Coimmunization Vaccine of Aβ42 Ameliorates Cognitive Deficits Without Brain Inflammation in an Alzheimer’s Disease Model

Macromolecular and small-molecule modulation of intracellular Aβ42 aggregation and associated toxicity.

Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

Bone-Marrow-Derived Microglia-Like Cells Ameliorate Brain Amyloid Pathology and Cognitive Impairment in a Mouse Model of Alzheimer's Disease

Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9

Active Beta-Amyloid Immunization Restores Spatial Learning in Pdapp Mice Displaying Very Low Levels of Beta-Amyloid

Effects of a Multimerized Recombinant Autoantibody Against Amyloid-β